Corvus reports Q2 2026 results, updates soquelitinib pipeline progress
Corvus reported enrollment progress in its Phase 3 PTCL and Phase 2 atopic dermatitis trials, new hidradenitis suppurativa and asthma studies planned this year, and $215.2 million in cash as of June 30, 2026.
SEC filing